• Company/University: Sygnature Discovery
• Interviewee: Dr Rebecca Allsopp (Senior Scientist)
• Products used: PHERAstar FSX

Sygnature Discovery is a Contract Research Organisation (CRO) specialized in supporting clients´ projects by providing integrated drug discovery resources. This is mainly achieved by assessing the pharmacology and functionality of novel compounds or targets.

Sygnature Discovery routinely utilises a plethora of biochemical assays including BRET, TR-FRET, HTRF, absorbance, fluorescence intensity and polarization and AlphaLISA in different microplate formats all of which are measured on the PHERAstar FSX. The microplate reader was chosen for its sensitivity, reliability and flexibility. The flexibility of the reader helps to match the diverse and changing needs CROs have to face when tackling different drug discovery projects. The sensitivity and consistent reliability enabled the design of very challenging bespoke assays that could to be performed on other assays.